NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

11080	Companies
243102	Keywords
171244	Articles
130868	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 05/15/2026 at 14:05, 4 months 9 days ago

NanoViricides Reports Progress on NV-387 in Latest SEC Filing

NanoViricides NV-387 Phase II Trial Orphan Drug Monkeypox Treatment
BRIEF

published on 05/15/2026 at 14:05, 4 months 9 days ago

NanoViricides fait état de progrès dans le développement du NV-387 dans son dernier document déposé auprès de la SEC.

NanoViricides NV-387 Essai De Phase II Médicament Orphelin Traitement De La Variole Du Singe
PRESS RELEASE

published on 05/15/2026 at 14:00, 4 months 9 days ago

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
NanoViricides, Inc. files Quarterly Report on Form 10-Q with the SEC. NV-387 advances in Phase II trial for Measles, MPox, and Smallpox treatments. Financial updates disclosed

NV-387 Form 10-Q NanoViricides Inc. Phase II Trial Financial Update
BRIEF

published on 05/11/2026 at 14:35, 4 months 13 days ago

NanoViricides souligne le besoin d'antiviraux à large spectre après l'incident du hantavirus

NanoViricides NV-387 Antiviral À Large Spectre Hantavirus MV Hondius
BRIEF

published on 05/11/2026 at 14:35, 4 months 13 days ago

NanoViricides Highlights Need for Broad-Spectrum Antivirals Post-Hantavirus Incident

NanoViricides NV-387 Broad-spectrum Antiviral Hantavirus MV Hondius
PRESS RELEASE

published on 05/11/2026 at 14:30, 4 months 13 days ago

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
NanoViricides, Inc. highlights the need for a revolutionary antiviral drug like NV-387 as response to Andes hantavirus incident on a cruise ship, emphasizing potential global epidemic risk

NV-387 NanoViricides Inc. Antiviral Drug Andes Hantavirus Global Epidemic
BRIEF

published on 05/04/2026 at 14:35, 4 months 20 days ago

NanoViricides' NV-387 Receives Orphan Drug Designation for Measles Treatment

NanoViricides NV-387 Orphan Drug Designation Measles Treatment US FDA
BRIEF

published on 05/04/2026 at 14:35, 4 months 20 days ago

Le NV-387 de NanoViricides obtient la désignation de médicament orphelin pour le traitement de la rougeole

NanoViricides NV-387 Désignation De Médicament Orphelin FDA Américaine Traitement De La Rougeole
PRESS RELEASE

published on 05/04/2026 at 14:30, 4 months 20 days ago

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
NanoViricides, Inc. receives US FDA Orphan Drug Designation for antiviral drug NV-387, targeting Measles treatment. The drug shows strong efficacy in in vivo studies

NanoViricides NV-387 Orphan Drug Designation Antiviral Drug Measles Treatment
BRIEF

published on 04/21/2026 at 14:35, 5 months 3 days ago

NV-387 Emerges as a Critical Solution in Combating Measles Outbreaks

Global Health Vaccination Measles Outbreak NV-387 Treatment Pediatric Disease

Accesswire

Published on 09/24/2026 at 22:01, 2 hours 19 minutes ago

Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 17:45, 6 hours 35 minutes ago

Jo-Jo Announces Resignation of Director
Published on 09/24/2026 at 14:55, 9 hours 25 minutes ago

Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/24/2026 at 14:30, 9 hours 50 minutes ago

Solitario Resources CEO to Present at the 38th Annual Mining Forum Americas 2026 Conference
Published on 09/24/2026 at 14:00, 10 hours 20 minutes ago

Horizon Aircraft to Report First Quarter 2027 Results and Provide a Business Update on October 9, 2026

View all ACCESSWIRE

EQS Group

Published on 09/24/2026 at 20:29, 3 hours 51 minutes ago

EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 5 hours 20 minutes ago

HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 5 hours 39 minutes ago

EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:15, 6 hours 5 minutes ago

Epanko Value Engineering Identifies 20% Production Increase
Published on 09/24/2026 at 18:05, 6 hours 14 minutes ago

DCK Tools Showcases Expanded Outdoor Power Equipment Lineup at Salonvert 2026

Les Echos

Published on 09/24/2026 at 18:31, 5 hours 48 minutes ago

LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:10, 6 hours 10 minutes ago

Financial statements - 30 june 2026
Published on 09/24/2026 at 18:00, 6 hours 20 minutes ago

GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 6 hours 20 minutes ago

GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 09/24/2026 at 18:00, 6 hours 20 minutes ago

i2S : Résultats 1er semestre 2026

View all LES ECHOS COMFI WIRE